Phosphatidylinositol-3-Kinase Signaling Is Required for Erythropoietin-Mediated Acute Protection Against Myocardial Ischemia/Reperfusion Injury-Reference-Cited by-同舟云学术

Phosphatidylinositol-3-Kinase Signaling Is Required for Erythropoietin-Mediated Acute Protection Against Myocardial Ischemia/Reperfusion Injury

Published:2004-05-04 Issue:17 Volume:109 Page:2050-2053
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Cai Zheqing¹,Semenza Gregg L.¹

Affiliation:

1. From the Institute for Cell Engineering, McKusick-Nathans Institute of Genetic Medicine, and Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Md.

Abstract

Background— Parenteral administration of recombinant human erythropoietin (rhEPO) to rats induces protection against myocardial ischemia/reperfusion injury 24 hours later. However, the mechanisms by which rhEPO mediates protection have not been determined. Methods and Results— rhEPO was perfused into isolated rat hearts over 15 minutes immediately before 30 minutes of no-flow ischemia and 45 minutes of reperfusion. Compared with saline-perfused control hearts, recovery of left ventricular developed pressure was increased in rhEPO-perfused hearts. rhEPO also increased AKT activity and decreased apoptosis. All of these effects were blocked when the phosphatidylinositol-3-kinase inhibitor wortmannin was infused with rhEPO. Conclusions— rhEPO provides immediate protection against ischemia/reperfusion injury in the isolated perfused rat heart that is mediated by the phosphatidylinositol-3-kinase pathway.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.0000127954.98131.23

Reference17 articles.

1. Myocyte apoptosis: programming ventricular remodeling**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.

2. Protective responses in the ischemic myocardium

3. Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia-Reperfusion Injury

4. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

5. A novel protective effect of erythropoietin in the infarcted heart

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuronal nitric oxide synthase required for erythropoietin modulation of heart function in mice;Frontiers in Physiology;2024-04-02

2. The nongenomic neuroprotective effects of estrogen, E2-BSA, and G1 following traumatic brain injury: PI3K/Akt and histopathological study;Hormone Molecular Biology and Clinical Investigation;2024-03-01

3. Design and synthesis of 3,4-seco-lupane triterpene derivatives to resist myocardial ischemia-reperfusion injury by inhibiting oxidative stress-mediated mitochondrial dysfunction via the PI3K/AKT/HIF-1α axis;Biomedicine & Pharmacotherapy;2023-11

4. Prostaglandin E2 mediates the late phase of ischemic preconditioning in the heart via its receptor subtype EP4;Heart and Vessels;2022-12-16

5. Sodium danshensu attenuates cerebral ischemia–reperfusion injury by targeting AKT1;Frontiers in Pharmacology;2022-09-15